Fred Meadows, Ph. D. will develop and direct CHPA’s science-based policy and implement action plans for technical and regulatory issues, while Caitlin Ondracek, Ph. D. will develop and support regulatory and scientific affairs activities, including programs with the U.S. Food and Drug Administration (FDA) and ingredient safety.
(WASHINGTON, D.C.) – The Consumer Healthcare Products Association (CHPA) today announced the recent hiring of Dr. Fred Meadows as its new Senior Director of Quality, Technical, and Regulatory Affairs and Dr. Caitlin Ondracek as its new Senior Director of Medical Science and Regulatory Affairs. Meadows will report to Dr. Marcia Howard, Vice President of Regulatory and Scientific Affairs, and Ondracek will report to Dr. Jay Sirois, Vice President of Regulatory and Scientific Affairs.
With more than two decades of experience in the pharmaceuticals, medical devices, and chemical industries, Meadows joins CHPA from U.S. Pharmacopeia (USP), where he most recently served as the Senior Technical Advisor for Product Supply Management and Chemistry Manufacturing and Controls (CMC). In his previous role, Meadows led CMC teams across 16 countries in Asia and Africa, providing technical guidance to pharmaceutical manufacturers to resolve issues and meet Good Manufacturing Practices (GMP) and Quality Management System (QMS) standards and attain marketing authorization for active pharmaceutical ingredients and finished pharmaceutical products.
“We’re thrilled to welcome Fred to CHPA,” said Howard, “and confident that his decades of expertise and leadership will not only strengthen our internal team but add significant value to our member companies.”
"I’m honored to join CHPA as a regulatory and scientific affairs specialist,” said Meadows. “I look forward to working alongside such a skilled team to tackle key industry issues, navigate regulatory challenges, and advance meaningful outcomes that ensure consumers have continued access to beneficial self-care products.”
Ondracek joins CHPA from the Association for Diagnostics & Laboratory Medicine (ADLM), where she previously served as Director of Science and Practice Programs, managing and modernizing the association’s 21 scientific divisions, and leading key scientific initiatives including the COVID Immunity Study and the ADLM blood sample bank. She has more than a decade of experience in biomedical research and nearly a decade in the non-profit sector.
"Caitlin’s extensive knowledge and strategic insights will not only enhance our team’s capabilities,” said Sirois, “but deliver meaningful benefits to our member companies as we navigate the complex and ever-evolving self-care landscape.”
"I’m excited to join CHPA’s regulatory and scientific affairs department,” said Ondracek. “I look forward to collaborating with this talented team and applying my extensive background in biomedical research to address critical industry challenges and contribute to delivering value for our member companies in today’s dynamic healthcare environment."
